MedTrace Logo

NC Testing in LC & POTS

NCT05914649 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-05-07

No results posted yet for this study

Summary

Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Post-Acute Sequelae of COVID (PASC, or "Long COVID") experience cognitive dysfunction. The investigators will test the hypothesis that 999 mL of IV saline will improve cognitive function in patients with POTS and Long COVID compared to placebo (50 mL of saline).

Conditions

  • Postural Orthostatic Tachycardia Syndrome
  • Post Acute Sequelae of SARS CoV 2 Infection

Interventions

OTHER

IV normal saline (999 mL infusion)

999 mL of IV normal saline will be infused intravenously

OTHER

IV normal saline (50 mL infusion)

50 mL of IV normal saline will be infused intravenously as a placebo control.

Sponsors & Collaborators

  • University of Calgary

    lead OTHER

Principal Investigators

  • Satish R Raj, MD MSCI · University of Calgary

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-19
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05914649 on ClinicalTrials.gov